» Articles » PMID: 26474317

MDS Research Criteria for Prodromal Parkinson's Disease

Abstract

This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease-modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available.

Citing Articles

Male sex accelerates cognitive decline in GBA1 Parkinson's disease.

Caminiti S, Avenali M, Galli A, Malito R, Cuconato G, Galandra C NPJ Parkinsons Dis. 2025; 11(1):41.

PMID: 40038314 PMC: 11880540. DOI: 10.1038/s41531-025-00883-7.


Cholinergic degeneration and early cognitive signs in prodromal Lewy body dementia.

Woo K, Kim H, Kim R, Jin B, Shin J, Kim S Alzheimers Dement. 2025; 21(2):e14584.

PMID: 39985502 PMC: 11846479. DOI: 10.1002/alz.14584.


Healthcare use is elevated two decades before a first demyelinating event and differs by age and sex.

Tremlett H, Zhu F, Everett K, Asaf A, Manouchehrinia A, Li P Ann Clin Transl Neurol. 2025; 12(2):415-432.

PMID: 39887956 PMC: 11822793. DOI: 10.1002/acn3.52267.


Toward a biological definition of neuronal and glial synucleinopathies.

Soto C, Mollenhauer B, Hansson O, Kang U, Alcalay R, Standaert D Nat Med. 2025; 31(2):396-408.

PMID: 39885358 DOI: 10.1038/s41591-024-03469-7.


Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.

Bolsewig K, Willemse E, Sanchez-Juan P, Rabano A, Martinez M, Doecke J Nat Commun. 2025; 16(1):1139.

PMID: 39881147 PMC: 11779843. DOI: 10.1038/s41467-025-56293-z.